NBL-015
Highest phase reached
Phase 1
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Protein
- Drug name
- NBL-015
- Fully human monoclonal IgG1 antibody against the type 2 isoform of human Claudin 18 protein (Claudin 18.2).
- fully human monoclonal igg1 antibody against the type 2 isoform of human claudin 18 protein claudin 18 2
- nbl 015
- nbl 015 anti claudin18 2 mab
- Nbl-015
- NBL-015
- Nbl-015 (anti-claudin18.2 mab)
- ChEMBL ID
- CHEMBL5314994
- FDA ingredient codes (UNII)
- 7EM2VXC85Q
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
Open Targets indications
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
Trial references
- NCT05153096
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (3)
- Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
- Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
- Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
In development for (1)
- Neoplasm Phase 1